Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.8K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.3K
Chemical Synapses01:26

Chemical Synapses

9.0K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
9.0K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.0K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.0K
Muscle Contraction01:10

Muscle Contraction

6.9K
In skeletal muscles, acetylcholine is released by nerve terminals at the motor endplate—the point of synaptic communication between motor neurons and muscle fibers. The binding of acetylcholine to its receptors on the sarcolemma allows entry of sodium ions into the cell and triggers an action potential in the muscle cell. Thus, electrical signals from the brain are transmitted to the muscle. Subsequently, the enzyme acetylcholinesterase breaks down acetylcholine to prevent excessive...
6.9K
Complementation Tests00:49

Complementation Tests

5.1K
A complementation test is a simple cross to identify whether the two mutations are located on the same gene or different genes. It was first performed by Edward Lewis in the 1940s while working on fruit flies. He developed the test to identify the location and arrangement of different mutations on chromosomes.
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The EBV-autoimmunity axis: mechanistic insights in SLE, MS and PSC.

Immunology and cell biology·2026
Same author

Myelin antigen capture in the CNS by B cells expressing EBV latent membrane protein 1 leads to demyelinating lesion formation.

Cell·2026
Same author

Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5.

Brain : a journal of neurology·2023
Same author

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis.

Therapeutic advances in neurological disorders·2023
Same author

Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities.

Acta neuropathologica·2022
Same author

High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis.

Proceedings of the National Academy of Sciences of the United States of America·2022

Related Experiment Video

Updated: Aug 29, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.5K

Complement and myasthenia gravis.

Nicholas S R Sanderson1

  • 1Department of Biomedicine, University Hospital Basel, Switzerland.

Molecular Immunology
|September 5, 2022
PubMed
Summary
This summary is machine-generated.

Myasthenia gravis involves antibodies attacking the neuromuscular junction. Complement activation, specifically the membrane attack complex, is crucial in damaging the postsynaptic membrane, leading to disease pathology.

Keywords:
AChRAntigen arraysAutoantibodiesComplementCross-linkingMyasthenia gravis

More Related Videos

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy
12:18

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

Published on: December 26, 2014

21.9K
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

11.6K

Related Experiment Videos

Last Updated: Aug 29, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.5K
The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy
12:18

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

Published on: December 26, 2014

21.9K
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

11.6K

Area of Science:

  • Neurology
  • Immunology
  • Molecular Biology

Background:

  • Myasthenia gravis (MG) is an autoimmune neuromuscular disease.
  • It is characterized by autoantibodies targeting components at the neuromuscular junction, primarily the acetylcholine receptor (AChR).

Purpose of the Study:

  • To review the evidence supporting the role of complement activation in MG pathogenesis.
  • To explore the relationship between autoantigens, autoantibodies, and complement-mediated destruction of the postsynaptic membrane.
  • To discuss recent findings on complement-inhibiting therapies like eculizumab and their structural mechanisms.

Main Methods:

  • Review of existing scientific literature and evidence.
  • Analysis of the mechanisms linking autoantibody binding to complement activation.
  • Consideration of structural viewpoints on antibody-complement interactions.

Main Results:

  • Convincing evidence implicates complement membrane attack complex in destroying the AChR-bearing postsynaptic membrane.
  • The review discusses the interplay between autoantigens, autoantibodies, and complement activation in MG.
  • Recent data on eculizumab provides insights into complement inhibition strategies.

Conclusions:

  • Complement activation is central to the pathology of myasthenia gravis.
  • Understanding the structural basis of antibody-complement interactions is key for therapeutic development.
  • Targeting complement pathways offers a promising therapeutic avenue for MG.